DLA Piper advises Ingenix.AI on securing EUR9 million in seed funding

Global law firm DLA Piper has advised Ingenix.AI, a breakthrough biotech AI startup, on securing EUR 9 million in seed funding from Inovo Venture Partners, OTB Ventures, and the International Finance Corporation (IFC). Ingenix is a disruptive, proprietary multimodal and multiscale generative AI co-pilot for clinical development, created to enable accurate simulation of clinical drug trials.

The funding alongside the support of renowned investors, will enable Ingenix to further develop its advanced AI platform, potentially revolutionising the way clinical trials are conducted worldwide.

Ingenix's proprietary model analyses biological phenomena at the molecular, cellular, and population levels, enabling clinical trial outcomes to be predicted with unprecedented accuracy. This technology allows the pharmaceutical industry to significantly increase the effectiveness of clinical trials, accelerate the development of new therapies, and minimise the risk of failure.

A cross-border team from DLA Piper's Warsaw, Leeds, and London offices worked on the transaction led by Corporate partner Rafał Kluziak. They were supported by partner Amar Maan (Corporate), counsels Wojciech Kalinowski, and Anna Chrabota-Bajson, senior associate Julian Bajada, junior associates Michał Bandurski and Konrad Nazarowski.

“Supporting Ingenix.AI at this crucial stage of their development is a significant milestone and highlights the growing importance of AI technology in business, particularly in the biotechnology sector. Our international footprint and seamless coordination allowed us to ensure that we effectively navigated legal complexity into commercial success for Ingenix.AI to receive funding, allowing them to scale their groundbreaking work on transforming clinical trials. This transaction is testament to our capabilities around the AI sector and follows closely on the back of our successful work with Applica.AI."